ID   BUB1B_HUMAN             Reviewed;        1050 AA.
AC   O60566; B2R6U0; B4DL09; B4DLG3; O60501; O60627; O60758; O75389;
AC   Q59HH6; Q8WV50; Q96KM4;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 3.
DT   05-OCT-2010, entry version 109.
DE   RecName: Full=Mitotic checkpoint serine/threonine-protein kinase BUB1 beta;
DE            EC=2.7.11.1;
DE   AltName: Full=MAD3/BUB1-related protein kinase;
DE            Short=hBUBR1;
DE   AltName: Full=Mitotic checkpoint kinase MAD3L;
DE   AltName: Full=Protein SSK1;
GN   Name=BUB1B; Synonyms=BUBR1, MAD3L, SSK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-349.
RC   TISSUE=Umbilical vein;
RX   MEDLINE=98289625; PubMed=9618306; DOI=10.1006/bbrc.1998.8713;
RA   Donadelli R., Benatti L., Remuzzi A., Morigi M., Gullans S.R.,
RA   Benigni A., Remuzzi G., Noris M.;
RT   "Identification of a novel gene -- SSK1 -- in human endothelial cells
RT   exposed to shear stress.";
RL   Biochem. Biophys. Res. Commun. 246:881-887(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-349.
RX   MEDLINE=98327111; PubMed=9660858; DOI=10.1083/jcb.142.1.1;
RA   Taylor S.S., Ha E., McKeon F.;
RT   "The human homologue of Bub3 is required for kinetochore localization
RT   of Bub1 and a Mad3/Bub1-related protein kinase.";
RL   J. Cell Biol. 142:1-11(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH CENPE,
RP   SUBCELLULAR LOCATION, AND VARIANT GLN-349.
RX   MEDLINE=98437347; PubMed=9763420; DOI=10.1083/jcb.143.1.49;
RA   Chan G.K.T., Schaar B.T., Yen T.J.;
RT   "Characterization of the kinetochore binding domain of CENP-E reveals
RT   interactions with the kinetochore proteins CENP-F and hBUBR1.";
RL   J. Cell Biol. 143:49-63(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS THR-15 AND
RP   GLN-349.
RX   MEDLINE=98180623; PubMed=9521327; DOI=10.1038/32688;
RA   Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K.V.,
RA   Markowitz S.D., Kinzler K.W., Vogelstein B.;
RT   "Mutations of mitotic checkpoint genes in human cancers.";
RL   Nature 392:300-303(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=99107817; PubMed=9889005; DOI=10.1006/geno.1998.5629;
RA   Davenport J.W., Fernandes E.R., Harris L.D., Neale G.A.M., Goorha R.;
RT   "The mouse mitotic checkpoint gene bub1b, a novel bub1 family member,
RT   is expressed in a cell cycle-dependent manner.";
RL   Genomics 55:113-117(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-349.
RA   Dai W., Ouyang B., Lan Z., Pan H.;
RT   "Human MAD3-like protein kinase (hmad3).";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Seike M., Gemma A., Hosoya Y., Kurimoto F., Yoshimura A., Kudoh S.;
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   VARIANT GLN-349.
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   GLN-349 AND SER-378.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PHOSPHORYLATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=10593653;
RA   Li W., Lan Z., Wu H., Wu S., Meadows J., Chen J., Zhu V., Dai W.;
RT   "BUBR1 phosphorylation is regulated during mitotic checkpoint
RT   activation.";
RL   Cell Growth Differ. 10:769-775(1999).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INDUCTION, PHOSPHORYLATION, AND
RP   INTERACTION WITH APC/C.
RX   PubMed=10477750; DOI=10.1083/jcb.146.5.941;
RA   Chan G.K., Jablonski S.A., Sudakin V., Hittle J.C., Yen T.J.;
RT   "Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E
RT   functions at kinetochores and binds the cyclosome/APC.";
RL   J. Cell Biol. 146:941-954(1999).
RN   [13]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH CDC20 AND BUB3, AND
RP   MUTAGENESIS OF LYS-795.
RX   PubMed=11702782; DOI=10.1016/S1534-5807(01)00019-3;
RA   Tang Z., Bharadwaj R., Li B., Yu H.;
RT   "Mad2-independent inhibition of APC/Cdc20 by the mitotic checkpoint
RT   protein BubR1.";
RL   Dev. Cell 1:227-237(2001).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DEGRADATION BY THE PROTEASOME.
RX   PubMed=14706340; DOI=10.1016/S1535-6108(03)00302-7;
RA   Shin H.J., Baek K.H., Jeon A.H., Park M.T., Lee S.J., Kang C.M.,
RA   Lee H.S., Yoo S.H., Chung D.H., Sung Y.C., McKeon F., Lee C.W.;
RT   "Dual roles of human BubR1, a mitotic checkpoint kinase, in the
RT   monitoring of chromosomal instability.";
RL   Cancer Cell 4:483-497(2003).
RN   [15]
RP   ENZYME REGULATION, INTERACTION WITH CENPE, AUTOPHOSPHORYLATION, AND
RP   MUTAGENESIS OF LYS-795.
RX   MEDLINE=22806743; PubMed=12925705; DOI=10.1083/jcb.200303167;
RA   Weaver B.A., Bonday Z.Q., Putkey F.R., Kops G.J., Silk A.D.,
RA   Cleveland D.W.;
RT   "Centromere-associated protein-E is essential for the mammalian
RT   mitotic checkpoint to prevent aneuploidy due to single chromosome
RT   loss.";
RL   J. Cell Biol. 162:551-563(2003).
RN   [16]
RP   FUNCTION.
RX   PubMed=15020684; DOI=10.1242/jcs.01006;
RA   Johnson V.L., Scott M.I., Holt S.V., Hussein D., Taylor S.S.;
RT   "Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-
RT   F and Mad2, and chromosome congression.";
RL   J. Cell Sci. 117:1577-1589(2004).
RN   [17]
RP   CASPASE-3 CLEAVAGE AT ASP-579 AND ASP-610, INDUCTION, AND MUTAGENESIS
RP   OF ASP-579 AND ASP-610.
RX   PubMed=16227576; DOI=10.1128/MCB.25.21.9232-9248.2005;
RA   Kim M., Murphy K., Liu F., Parker S.E., Dowling M.L., Baff W.,
RA   Kao G.D.;
RT   "Caspase-mediated specific cleavage of BubR1 is a determinant of
RT   mitotic progression.";
RL   Mol. Cell. Biol. 25:9232-9248(2005).
RN   [18]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PLK1.
RX   PubMed=16760428; DOI=10.1091/mbc.E06-03-0240;
RA   Qi W., Tang Z., Yu H.;
RT   "Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is
RT   required for the kinetochore localization of Plk1.";
RL   Mol. Biol. Cell 17:3705-3716(2006).
RN   [19]
RP   INTERACTION WITH CASC5, AND MUTAGENESIS OF ALA-159 AND PHE-175.
RX   PubMed=17981135; DOI=10.1016/j.devcel.2007.09.005;
RA   Kiyomitsu T., Obuse C., Yanagida M.;
RT   "Human Blinkin/AF15q14 is required for chromosome alignment and the
RT   mitotic checkpoint through direct interaction with Bub1 and BubR1.";
RL   Dev. Cell 13:663-676(2007).
RN   [20]
RP   INTERACTION WITH PLK1, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   SER-676, AND MUTAGENESIS OF THR-620.
RX   PubMed=17785528; DOI=10.1101/gad.436007;
RA   Elowe S., Huemmer S., Uldschmid A., Li X., Nigg E.A.;
RT   "Tension-sensitive Plk1 phosphorylation on BubR1 regulates the
RT   stability of kinetochore microtubule interactions.";
RL   Genes Dev. 21:2205-2219(2007).
RN   [21]
RP   INTERACTION WITH PLK1, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT
RP   THR-792 AND THR-1008.
RX   PubMed=17376779; DOI=10.1074/jbc.M611053200;
RA   Matsumura S., Toyoshima F., Nishida E.;
RT   "Polo-like kinase 1 facilitates chromosome alignment during
RT   prometaphase through BubR1.";
RL   J. Biol. Chem. 282:15217-15227(2007).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=19007248; DOI=10.1021/ac801708p;
RA   Wang B., Malik R., Nigg E.A., Korner R.;
RT   "Evaluation of the low-specificity protease elastase for large-scale
RT   phosphoproteome analysis.";
RL   Anal. Chem. 80:9526-9533(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-54, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-670, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435 AND SER-670, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   PHOSPHORYLATION AT SER-435; SER-543; SER-670 AND SER-1043.
RX   PubMed=19015317; DOI=10.1083/jcb.200805163;
RA   Huang H., Hittle J., Zappacosta F., Annan R.S., Hershko A., Yen T.J.;
RT   "Phosphorylation sites in BubR1 that regulate kinetochore attachment,
RT   tension, and mitotic exit.";
RL   J. Cell Biol. 183:667-680(2008).
RN   [27]
RP   SUMOYLATION.
RX   PubMed=18374647; DOI=10.1016/j.molcel.2008.01.013;
RA   Zhang X.-D., Goeres J., Zhang H., Yen T.J., Porter A.C.G.,
RA   Matunis M.J.;
RT   "SUMO-2/3 modification and binding regulate the association of CENP-E
RT   with kinetochores and progression through mitosis.";
RL   Mol. Cell 29:729-741(2008).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1043, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [30]
RP   FUNCTION.
RX   PubMed=19411850;
RA   Park S.-Y., Kim S., Cho H., Kwon S.-H., Chae S., Kang D., Seong Y.-S.,
RA   Cho H.;
RT   "Depletion of BubR1 promotes premature centrosomal localization of
RT   cyclin B1 and accelerates mitotic entry.";
RL   Cell Cycle 8:1754-1764(2009).
RN   [31]
RP   INTERACTION WITH CENPE, AND SUBCELLULAR LOCATION.
RX   PubMed=19625775;
RA   Huang Y., Yao Y., Xu H.-Z., Wang Z.-G., Lu L., Dai W.;
RT   "Defects in chromosome congression and mitotic progression in KIF18A-
RT   deficient cells are partly mediated through impaired functions of
RT   CENP-E.";
RL   Cell Cycle 8:2643-2649(2009).
RN   [32]
RP   INTERACTION WITH PCAF, ACETYLATION AT LYS-250, AND UBIQUITINATION.
RX   PubMed=19407811; DOI=10.1038/emboj.2009.123;
RA   Choi E., Choe H., Min J., Choi J.Y., Kim J., Lee H.;
RT   "BubR1 acetylation at prometaphase is required for modulating APC/C
RT   activity and timing of mitosis.";
RL   EMBO J. 28:2077-2089(2009).
RN   [33]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PLK1.
RX   PubMed=19503101; DOI=10.1038/onc.2009.141;
RA   Izumi H., Matsumoto Y., Ikeuchi T., Saya H., Kajii T., Matsuura S.;
RT   "BubR1 localizes to centrosomes and suppresses centrosome
RT   amplification via regulating Plk1 activity in interphase cells.";
RL   Oncogene 28:2806-2820(2009).
RN   [34]
RP   VARIANTS GLN-349 AND ALA-618.
RX   MEDLINE=99296833; PubMed=10366450; DOI=10.1006/geno.1999.5831;
RA   Cahill D.P., da Costa L.T., Carson-Walter E.B., Kinzler K.W.,
RA   Vogelstein B., Lengauer C.;
RT   "Characterization of MAD2B and other mitotic spindle checkpoint
RT   genes.";
RL   Genomics 58:181-187(1999).
RN   [35]
RP   VARIANTS MVA GLN-550; HIS-814; PHE-844; THR-909; HIS-921 AND PRO-1012.
RX   PubMed=15475955; DOI=10.1038/ng1449;
RA   Hanks S., Coleman K., Reid S., Plaja A., Firth H., Fitzpatrick D.,
RA   Kidd A., Mehes K., Nash R., Robin N., Shannon N., Tolmie J.,
RA   Swansbury J., Irrthum A., Douglas J., Rahman N.;
RT   "Constitutional aneuploidy and cancer predisposition caused by
RT   biallelic mutations in BUB1B.";
RL   Nat. Genet. 36:1159-1161(2004).
RN   [36]
RP   VARIANT PCS GLN-36.
RX   PubMed=16411201; DOI=10.1002/ajmg.a.31069;
RA   Matsuura S., Matsumoto Y., Morishima K., Izumi H., Matsumoto H.,
RA   Ito E., Tsutsui K., Kobayashi J., Tauchi H., Kajiwara Y., Hama S.,
RA   Kurisu K., Tahara H., Oshimura M., Komatsu K., Ikeuchi T., Kajii T.;
RT   "Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint
RT   in seven families with premature chromatid separation (PCS)
RT   syndrome.";
RL   Am. J. Med. Genet. A 140:358-367(2006).
RN   [37]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-40; GLN-349; ASP-390 AND ALA-618.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Essential component of the mitotic checkpoint. Required
CC       for normal mitosis progression. The mitotic checkpoint delays
CC       anaphase until all chromosomes are properly attached to the
CC       mitotic spindle. One of its checkpoint functions is to inhibit the
CC       activity of the anaphase-promoting complex/cyclosome (APC/C) by
CC       blocking the binding of CDC20 to APC/C, independently of its
CC       kinase activity. The other is to monitor kinetochore activities
CC       that depend on the kinetochore motor CENPE. Required for
CC       kinetochore localization of CENPE. Negatively regulates PLK1
CC       activity in interphase cells and suppresses centrosome
CC       amplification. Also implicated in triggering apoptosis in
CC       polyploid cells that exit aberrantly from mitotic arrest. May play
CC       a role for tumor suppression.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Kinase activity stimulated by CENPE.
CC   -!- SUBUNIT: Interacts with CENPE, CENPF, mitosin, PLK1 and BUB3. Part
CC       of a complex containing BUB3, CDC20 and BUB1B. Interacts with
CC       anaphase-promoting complex/cyclosome (APC/C). Interacts with
CC       CASC5.
CC   -!- INTERACTION:
CC       Q12834:CDC20; NbExp=4; IntAct=EBI-1001438, EBI-367462;
CC       Q02224:CENPE; NbExp=2; IntAct=EBI-1001438, EBI-1375040;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Chromosome, centromere,
CC       kinetochore. Cytoplasm, cytoskeleton, centrosome. Note=Cytoplasmic
CC       in interphase cells. Associates with the kinetochores in early
CC       prophase. Kinetochore localization requires BUB1, PLK1 and CASC5.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O60566-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O60566-2; Sequence=VSP_036474, VSP_036475, VSP_036476;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=O60566-3; Sequence=VSP_036473;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Highly expressed in thymus followed by spleen.
CC       Preferentially expressed in tissues with a high mitotic index.
CC   -!- INDUCTION: Induced during mitosis.
CC   -!- DOMAIN: The D-box targets the protein for rapid degradation by
CC       ubiquitin-dependent proteolysis during the transition from mitosis
CC       to interphase (Potential).
CC   -!- DOMAIN: The BUB1 N-terminal domain directs kinetochore
CC       localization and binding to BUB3.
CC   -!- PTM: Proteolytically cleaved by caspase-3 in a cell cycle specific
CC       manner. The cleavage might be involved in the durability of the
CC       cell cycle delay. Caspase-3 cleavage is associated with abrogation
CC       of the mitotic checkpoint. The major site of cleavage is at Asp-
CC       610.
CC   -!- PTM: Acetylation at Lys-250 regulates its degradation and timing
CC       in anaphase entry.
CC   -!- PTM: Ubiquitinated. Degradated by the proteasome.
CC   -!- PTM: Sumoylated by SUMO2 and SUMO3. The sumoylation mediates the
CC       association with CENPE at the kinetochore.
CC   -!- PTM: Autophosphorylated in vitro. Intramolecular
CC       autophosphorylation is stimulated by CENPE. Phosphorylated during
CC       mitosis and hyperphosphorylated in mitotically arrested cells.
CC       Phosphorylation at Ser-670 and Ser-1043 occurs at kinetochores
CC       upon mitotic entry with dephosphorylation at the onset of
CC       anaphase.
CC   -!- DISEASE: Note=Defects in BUB1B are associated with tumor
CC       formation.
CC   -!- DISEASE: Defects in BUB1B are the cause of premature chromatid
CC       separation trait (PCS) [MIM:176430]. PCS consists of separate and
CC       splayed chromatids with discernible centromeres and involves all
CC       or most chromosomes of a metaphase. It is found in up to 2% of
CC       metaphases in cultured lymphocytes from approximately 40% of
CC       normal individuals. When PCS is present in 5% or more of cells, it
CC       is known as the heterozygous PCS trait and has no obvious
CC       phenotypic effect, although some have reported decreased
CC       fertility. Inheritance is autosomal dominant.
CC   -!- DISEASE: Defects in BUB1B are the cause of mosaic variegated
CC       aneuploidy syndrome (MVA) [MIM:257300]. MVA is a severe autosomal
CC       recessive developmental disorder characterized by mosaic
CC       aneuploidies, predominantly trisomies and monosomies, involving
CC       multiple different chromosomes and tissues. The proportion of
CC       aneuploid cells varies but is usually more than 25% and is
CC       substantially greater than in normal individuals. Affected
CC       individuals typically present with severe intrauterine growth
CC       retardation and microcephaly. Eye anomalies, mild dysmorphism,
CC       variable developmental delay, and a broad spectrum of additional
CC       congenital abnormalities and medical conditions may also occur.
CC       The risk of malignancy is high, with rhabdomyosarcoma, Wilms tumor
CC       and leukemia reported in several cases. MVA is caused by biallelic
CC       mutations in the BUB1B gene.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. BUB1 subfamily.
CC   -!- SIMILARITY: Contains 1 BUB1 N-terminal domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92019.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BUB1BID854ch15q15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF053306; AAC06260.1; -; mRNA.
DR   EMBL; AF046918; AAC33435.1; -; mRNA.
DR   EMBL; AF046079; AAC12730.2; -; mRNA.
DR   EMBL; AF107297; AAD11941.1; -; mRNA.
DR   EMBL; AF035933; AAC23736.1; -; mRNA.
DR   EMBL; AF068760; AAC19118.1; -; mRNA.
DR   EMBL; AF310214; AAL10712.1; -; Genomic_DNA.
DR   EMBL; AF310192; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310193; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310194; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310195; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310196; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310197; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310198; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310199; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310200; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310201; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310202; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310203; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310204; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310205; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310206; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310207; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310208; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310209; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310210; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310211; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310212; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AF310213; AAL10712.1; JOINED; Genomic_DNA.
DR   EMBL; AK296795; BAG59371.1; -; mRNA.
DR   EMBL; AK296984; BAG59525.1; -; mRNA.
DR   EMBL; AK312709; BAG35587.1; -; mRNA.
DR   EMBL; AB208782; BAD92019.1; ALT_INIT; mRNA.
DR   EMBL; BC018739; AAH18739.1; -; mRNA.
DR   IPI; IPI00141933; -.
DR   IPI; IPI00921844; -.
DR   IPI; IPI00922915; -.
DR   PIR; JW0092; JW0092.
DR   RefSeq; NP_001202.4; -.
DR   UniGene; Hs.513645; -.
DR   PDB; 2WVI; X-ray; 1.80 A; A=57-220.
DR   PDBsum; 2WVI; -.
DR   ProteinModelPortal; O60566; -.
DR   SMR; O60566; 793-985.
DR   DIP; DIP-24203N; -.
DR   IntAct; O60566; 40.
DR   STRING; O60566; -.
DR   PhosphoSite; O60566; -.
DR   PRIDE; O60566; -.
DR   Ensembl; ENST00000287598; ENSP00000287598; ENSG00000156970.
DR   GeneID; 701; -.
DR   KEGG; hsa:701; -.
DR   CTD; 701; -.
DR   GeneCards; GC15P040453; -.
DR   H-InvDB; HIX0012121; -.
DR   HGNC; HGNC:1149; BUB1B.
DR   HPA; HPA008419; -.
DR   MIM; 176430; phenotype.
DR   MIM; 257300; phenotype.
DR   MIM; 602860; gene.
DR   Orphanet; 1052; Mosaic variegated aneuploidy syndrome.
DR   PharmGKB; PA82; -.
DR   eggNOG; prNOG18952; -.
DR   HOVERGEN; HBG050748; -.
DR   InParanoid; O60566; -.
DR   OMA; WDFYINL; -.
DR   OrthoDB; EOG91ZHWV; -.
DR   PhylomeDB; O60566; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Reactome; REACT_152; Cell Cycle, Mitotic.
DR   Reactome; REACT_1538; Cell Cycle Checkpoints.
DR   Reactome; REACT_383; DNA Replication.
DR   Reactome; REACT_6850; Cdc20:Phospho-APC/C mediated degradation of Cyclin A.
DR   Reactome; REACT_8017; APC-Cdc20 mediated degradation of Nek2A.
DR   NextBio; 2866; -.
DR   ArrayExpress; O60566; -.
DR   Bgee; O60566; -.
DR   CleanEx; HS_BUB1B; -.
DR   Genevestigator; O60566; -.
DR   GO; GO:0005680; C:anaphase-promoting complex; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0000940; C:outer kinetochore of condensed chromosome; IDA:UniProtKB.
DR   GO; GO:0051233; C:spindle midzone; NAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0031145; P:anaphase-promoting complex-dependent protea...; EXP:Reactome.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007067; P:mitosis; NAS:UniProtKB.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; TAS:ProtInc.
DR   GO; GO:0051436; P:negative regulation of ubiquitin-protein li...; EXP:Reactome.
DR   GO; GO:0048015; P:phosphoinositide-mediated signaling; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0034501; P:protein localization to kinetochore; IPI:UniProtKB.
DR   GO; GO:0007051; P:spindle organization; NAS:UniProtKB.
DR   InterPro; IPR015661; Bub1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR013212; Mad3_BUB1_I.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   PANTHER; PTHR14030; Bub1; 1.
DR   Pfam; PF08311; Mad3_BUB1_I; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00777; Mad3_BUB1_I; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51489; BUB1_N; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; FALSE_NEG.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Cell cycle; Cell division; Centromere; Chromosome;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Disease mutation; Kinase;
KW   Kinetochore; Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Serine/threonine-protein kinase; Transferase;
KW   Tumor suppressor; Ubl conjugation.
FT   CHAIN         1   1050       Mitotic checkpoint serine/threonine-
FT                                protein kinase BUB1 beta.
FT                                /FTId=PRO_0000085673.
FT   DOMAIN       62    226       BUB1 N-terminal.
FT   DOMAIN      766   1050       Protein kinase.
FT   NP_BIND     772    780       ATP (By similarity).
FT   REGION      152    185       Necessary for interaction with CASC5.
FT   MOTIF       111    118       Nuclear localization signal (Potential).
FT   MOTIF       224    232       D-box.
FT   COMPBIAS    209    215       Poly-Glu.
FT   ACT_SITE    882    882       Proton acceptor (By similarity).
FT   BINDING     795    795       ATP (By similarity).
FT   SITE        579    580       Cleavage; by caspase-3.
FT   SITE        610    611       Cleavage; by caspase-3.
FT   MOD_RES      54     54       Phosphothreonine.
FT   MOD_RES     250    250       N6-acetyllysine; by PCAF.
FT   MOD_RES     435    435       Phosphoserine.
FT   MOD_RES     543    543       Phosphoserine.
FT   MOD_RES     670    670       Phosphoserine.
FT   MOD_RES     676    676       Phosphoserine; by PLK1.
FT   MOD_RES     792    792       Phosphothreonine; by PLK1.
FT   MOD_RES    1008   1008       Phosphothreonine; by PLK1.
FT   MOD_RES    1043   1043       Phosphoserine.
FT   VAR_SEQ      80     80       R -> RWVFLFHKDNRNINR (in isoform 3).
FT                                /FTId=VSP_036473.
FT   VAR_SEQ     113    166       Missing (in isoform 2).
FT                                /FTId=VSP_036474.
FT   VAR_SEQ     522    522       K -> KVSLSL (in isoform 2).
FT                                /FTId=VSP_036475.
FT   VAR_SEQ     608    675       Missing (in isoform 2).
FT                                /FTId=VSP_036476.
FT   VARIANT      15     15       M -> T (in a colorectal cancer cell
FT                                line).
FT                                /FTId=VAR_008852.
FT   VARIANT      36     36       R -> Q (in PCS).
FT                                /FTId=VAR_028921.
FT   VARIANT      40     40       T -> M (in dbSNP:rs56079734).
FT                                /FTId=VAR_040402.
FT   VARIANT     349    349       R -> Q (in dbSNP:rs1801376).
FT                                /FTId=VAR_008853.
FT   VARIANT     378    378       P -> S (in dbSNP:rs17851677).
FT                                /FTId=VAR_054549.
FT   VARIANT     390    390       E -> D (in dbSNP:rs1017842).
FT                                /FTId=VAR_028922.
FT   VARIANT     550    550       R -> Q (in MVA; heterozygous compound
FT                                with nonsense mutation;
FT                                dbSNP:rs28989187).
FT                                /FTId=VAR_028923.
FT   VARIANT     618    618       V -> A (in colorectal cancer;
FT                                dbSNP:rs1801528).
FT                                /FTId=VAR_008854.
FT   VARIANT     814    814       R -> H (in MVA; heterozygous compound
FT                                with nonsense mutation;
FT                                dbSNP:rs28989182).
FT                                /FTId=VAR_028924.
FT   VARIANT     844    844       L -> F (in MVA; associated with H-921;
FT                                heterozygous compound with nonsense
FT                                mutation; dbSNP:rs28989181).
FT                                /FTId=VAR_028925.
FT   VARIANT     909    909       I -> T (in MVA; heterozygous compound
FT                                with nonsense mutation;
FT                                dbSNP:rs28989184).
FT                                /FTId=VAR_028926.
FT   VARIANT     921    921       Q -> H (in MVA; associated with F-844;
FT                                heterozygous compound with nonsense
FT                                mutation; dbSNP:rs28989183).
FT                                /FTId=VAR_028927.
FT   VARIANT    1012   1012       L -> P (in MVA; heterozygous compound
FT                                with nonsense mutation;
FT                                dbSNP:rs28989185).
FT                                /FTId=VAR_028928.
FT   MUTAGEN     159    159       A->W: Loss of interaction with CASC5.
FT   MUTAGEN     175    175       F->A: Loss of interaction with CASC5.
FT   MUTAGEN     579    579       D->E: Abolishes the cleavage by caspase-
FT                                3.
FT   MUTAGEN     610    610       D->E: Abolishes the cleavage by caspase-
FT                                3.
FT   MUTAGEN     620    620       T->A: Induces chromosome congression
FT                                defects and mitotic delay.
FT   MUTAGEN     795    795       K->A: Does not abolish the capacity to
FT                                inhibit APC/CDC20.
FT   MUTAGEN     795    795       K->R: Inhibits kinase activity.
FT   CONFLICT    248    249       AL -> VF (in Ref. 1; AAC23736).
FT   CONFLICT    283    283       S -> P (in Ref. 8; BAG35587).
FT   CONFLICT    788    788       S -> F (in Ref. 2; AAC06260).
FT   CONFLICT   1018   1018       E -> K (in Ref. 3; AAC33435).
SQ   SEQUENCE   1050 AA;  119545 MW;  F7871103A56E6B46 CRC64;
     MAAVKKEGGA LSEAMSLEGD EWELSKENVQ PLRQGRIMST LQGALAQESA CNNTLQQQKR
     AFEYEIRFYT GNDPLDVWDR YISWTEQNYP QGGKESNMST LLERAVEALQ GEKRYYSDPR
     FLNLWLKLGR LCNEPLDMYS YLHNQGIGVS LAQFYISWAE EYEARENFRK ADAIFQEGIQ
     QKAEPLERLQ SQHRQFQARV SRQTLLALEK EEEEEVFESS VPQRSTLAEL KSKGKKTARA
     PIIRVGGALK APSQNRGLQN PFPQQMQNNS RITVFDENAD EASTAELSKP TVQPWIAPPM
     PRAKENELQA GPWNTGRSLE HRPRGNTASL IAVPAVLPSF TPYVEETARQ PVMTPCKIEP
     SINHILSTRK PGKEEGDPLQ RVQSHQQASE EKKEKMMYCK EKIYAGVGEF SFEEIRAEVF
     RKKLKEQREA ELLTSAEKRA EMQKQIEEME KKLKEIQTTQ QERTGDQQEE TMPTKETTKL
     QIASESQKIP GMTLSSSVCQ VNCCARETSL AENIWQEQPH SKGPSVPFSI FDEFLLSEKK
     NKSPPADPPR VLAQRRPLAV LKTSESITSN EDVSPDVCDE FTGIEPLSED AIITGFRNVT
     ICPNPEDTCD FARAARFVST PFHEIMSLKD LPSDPERLLP EEDLDVKTSE DQQTACGTIY
     SQTLSIKKLS PIIEDSREAT HSSGFSGSSA SVASTSSIKC LQIPEKLELT NETSENPTQS
     PWCSQYRRQL LKSLPELSAS AELCIEDRPM PKLEIEKEIE LGNEDYCIKR EYLICEDYKL
     FWVAPRNSAE LTVIKVSSQP VPWDFYINLK LKERLNEDFD HFCSCYQYQD GCIVWHQYIN
     CFTLQDLLQH SEYITHEITV LIIYNLLTIV EMLHKAEIVH GDLSPRCLIL RNRIHDPYDC
     NKNNQALKIV DFSYSVDLRV QLDVFTLSGF RTVQILEGQK ILANCSSPYQ VDLFGIADLA
     HLLLFKEHLQ VFWDGSFWKL SQNISELKDG ELWNKFFVRI LNANDEATVS VLGELAAEMN
     GVFDTTFQSH LNKALWKVGK LTSPGALLFQ
//
